Researchers are studying many kinds of “other” treatments for mental health. These include short, fast-acting psychedelics (like 5‑MeO‑DMT and DMT/ayahuasca), new drugs that aim to rewire the brain without strong trips (called non-hallucinogenic psychoplastogens), traditional plant medicines used by healers, and new synthetic drugs that appear on the market. Studies range from lab work and single-case reports to small clinical trials and systematic reviews, so the evidence is mixed in size and quality (15122, 15082, 15077, 15118, 15099). Some results look promising. Several reports find short-term drops in depression, suicidal thinking, or alcohol use after psychedelic experiences, and laboratory work suggests these drugs can change brain activity and help the brain form new connections. But there are real risks, such as drug-induced hallucinations and a rare condition called HPPD (long-lasting changes in perception). Many findings are early, small, or inconsistent, and experts disagree about whether the intense, subjective experience of a psychedelic is needed for benefit (15093, 15122, 15082, 15080, 15097, 15077).